High‐Dose vs. Standard‐Dose Influenza Vaccine in Older Patients With Hypertension: A Post Hoc Analysis of DANFLU‐1
The Journal of Clinical Hypertension · 2025
DOI: 10.1111/jch.70177 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Hypertension, 2025. Verfasst von Adam Femerling Langhoff und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Hypertension. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Supported by Sanofi, which provided the HD-IIV doses along with a financial contribution covering remaining expenses. The protocol was codeveloped with the fun….
Abstract (Originalsprache)
Patients with hypertension (HTN) face an increased risk of complications and mortality from influenza; a risk that may be modified by influenza vaccination. There is limited evidence on the effectiveness of high‐dose (HD‐IIV) compared with standard‐dose (SD‐IIV) inactivated influenza vaccines in hypertensive individuals. This study, a post hoc analysis of DANFLU‐1, a pragmatic, and open‐label, individually randomized trial of HD‐IIV vs. SD‐IIV conducted during the 2021–2022 influenza season among participants aged 65–79 years. Prespecified outcomes in DANFLU‐1 included hospitalization for influenza or pneumonia, cardiovascular, cardiorespiratory, and respiratory hospitalizations, all‐cause hospitalization, and all‐cause mortality. Outcomes were analyzed as both time‐to‐first and recurrent events. DANFLU‐1 randomized 12 477 participants randomized to HD‐IIV or SD‐IIV, of these 6469 (51.9%) had a history of HTN. HD‐IIV was associated with lower hazards for hospitalizations for pneumonia or influenza, respiratory disease, and all‐cause mortality compared with SD‐IIV and these associations were consistent regardless of HTN status ( p interaction = 0.09, = 0.09, and = 0.59, respectively). HD‐IIV was associated with lower incidence rates of recurrent hospitalizations for pneumonia or influenza and all‐cause hospitalizations compared with SD‐IIV, irrespective of HTN status ( p interaction = 0.09 and = 0.75, respectively). There was evidence of potential effect modification of HD‐IIV vs. SD‐IIV in relation to recurrent respiratory hospitalizations, where the relative effect may be greater among those without vs. with HTN ( p interaction = 0.04). In conclusion, this post hoc analysis of a large‐scale pragmatic trial, HD‐IIV was associated with lower risk of clinical outcomes, including hospitalizations for pneumonia or influenza, all‐cause mortality, and all‐cause hospitalizations irrespective of the presence of HTN. Trial Registration : ClinicalTrials.gov identifier: NCT05048589
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark.
- Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Sanofi, Lyon, France.
- Sanofi, Swiftwater, Pennsylvania, USA.
- Sanofi, Singapore, Singapore.
- Department of Clinical Medicine - Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
ORCID-Profile: Adam Femerling Langhoff
Förderung
- Supported by Sanofi, which provided the HD-IIV doses along with a financial contribution covering remaining expenses. The protocol was codeveloped with the fun…
Zitieren
APA
Langhoff, A. F., Johansen, N. D., Modin, D., Janstrup, K. H., Bartholdy, K. V., Espersen, C., Nealon, J., Samson, S., Loiacono, M. M., Harris, R., Larsen, C. S., Jensen, A. M. R., Landler, N. E., Claggett, B. L., Solomon, S. D., Landray, M. J., Gislason, G. H., Køber, L., Sivapalan, P., …, & Biering-Sørensen, T. (2025). High‐Dose vs. Standard‐Dose Influenza Vaccine in Older Patients With Hypertension: A Post Hoc Analysis of DANFLU‐1. The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.70177
Vancouver
Langhoff AF, Johansen ND, Modin D, Janstrup KH, Bartholdy KV, Espersen C, et al. High‐Dose vs. Standard‐Dose Influenza Vaccine in Older Patients With Hypertension: A Post Hoc Analysis of DANFLU‐1. The Journal of Clinical Hypertension. 2025. doi:10.1111/jch.70177
BibTeX
@article{Langhoff2025,
author = {Langhoff, Adam Femerling and Johansen, Niklas Dyrby and Modin, Daniel and Janstrup, Kira Hyldekær and Bartholdy, Katja Vu and Espersen, Caroline and Nealon, Joshua and Samson, Sandrine and Loiacono, Matthew M and Harris, Rebecca and Larsen, Carsten Schade and Jensen, Anne Marie Reimer and Landler, Nino Emanuel and Claggett, Brian L and Solomon, Scott D and Landray, Martin J and Gislason, Gunnar H and Køber, Lars and Sivapalan, Pradeesh and Jensen, Jens Ulrik Stæhr and Biering-Sørensen, Tor},
title = {High‐Dose vs. Standard‐Dose Influenza Vaccine in Older Patients With Hypertension: A Post Hoc Analysis of DANFLU‐1},
journal = {The Journal of Clinical Hypertension},
year = {2025},
doi = {10.1111/jch.70177}
}
EUVIMED